company background image
ACHV logo

Achieve Life Sciences NasdaqCM:ACHV Stock Report

Last Price

US$4.52

Market Cap

US$95.7m

7D

-3.0%

1Y

-24.3%

Updated

27 Mar, 2024

Data

Company Financials +

Achieve Life Sciences, Inc.

NasdaqCM:ACHV Stock Report

Market Cap: US$95.7m

ACHV Stock Overview

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.

ACHV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Achieve Life Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Achieve Life Sciences
Historical stock prices
Current Share PriceUS$4.52
52 Week HighUS$10.30
52 Week LowUS$3.03
Beta1.33
1 Month Change10.51%
3 Month Change8.65%
1 Year Change-24.29%
3 Year Change-60.97%
5 Year Change-93.29%
Change since IPO-99.49%

Recent News & Updates

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

Jan 27
Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

Recent updates

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

Jan 27
Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Oct 26
Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Mar 26
Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22
Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27
Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14
We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01
We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

Shareholder Returns

ACHVUS BiotechsUS Market
7D-3.0%0.9%0.4%
1Y-24.3%10.3%28.8%

Return vs Industry: ACHV underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ACHV underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ACHV's price volatile compared to industry and market?
ACHV volatility
ACHV Average Weekly Movement8.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ACHV's share price has been volatile over the past 3 months.

Volatility Over Time: ACHV's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a20John Bencichhttps://www.achievelifesciences.com

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol.

Achieve Life Sciences, Inc. Fundamentals Summary

How do Achieve Life Sciences's earnings and revenue compare to its market cap?
ACHV fundamental statistics
Market capUS$95.67m
Earnings (TTM)-US$35.57m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACHV income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$35.57m
Earnings-US$35.57m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-1.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio401.1%

How did ACHV perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.